Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?
about
Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetesBergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective StudyNutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan.Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases.Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.Pharmacological management of diabetic dyslipidemia.Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9.Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea.Gallic Acid Improves Health-Associated Biochemical Parameters and Prevents Oxidative Damage of DNA in Type 2 Diabetes Patients: Results of a Placebo-Controlled Pilot Study.
P2860
Q24608214-187EE3B4-C84E-482F-B262-19CCF3162282Q36432198-687BF814-CF64-45E3-840B-3C0DEFFD0D06Q38231113-F301573C-228E-4015-A9CD-E3489D87831DQ38299279-07C95F94-B0D0-4D01-857E-7ABE86E61AAFQ38460480-58C81101-DF9D-4573-9659-48F1E15C8882Q39015072-EDA87FD6-9AB5-4E56-BD2D-AF082A026BC5Q47154672-42D3C379-C1ED-4255-B5C5-2773146A8AB9Q47330451-9B0B8D85-37C6-44C5-A9EA-9C3DF593726CQ49377852-2E2F6734-E50A-488E-9AD9-8D7C20146ABE
P2860
Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Should we measure routinely ox ...... subjects with type 2 diabetes?
@en
Should we measure routinely ox ...... subjects with type 2 diabetes?
@nl
type
label
Should we measure routinely ox ...... subjects with type 2 diabetes?
@en
Should we measure routinely ox ...... subjects with type 2 diabetes?
@nl
prefLabel
Should we measure routinely ox ...... subjects with type 2 diabetes?
@en
Should we measure routinely ox ...... subjects with type 2 diabetes?
@nl
P2093
P2860
P921
P1476
Should we measure routinely ox ...... subjects with type 2 diabetes?
@en
P2093
D Sakellariou
S Koulouris
S Pastromas
P2860
P304
P356
10.1111/J.1742-1241.2010.02378.X
P577
2010-09-09T00:00:00Z